OCEANSIX-FUTURE-PATHS-LT
15.2.2024 15:22:35 CET | Business Wire | Press release
oceansix Files Provisional Patent for Groundbreaking Packaging System
oceansix Future Paths Ltd. ("the Company" or "oceansix") is a publicly-traded Company on the TSX Venture Exchange in Toronto (TSXV: CUSIP 001194828, OSIX), in New York (OTCQB: AKMYF), and Frankfurt Stock Exchange (WKN: A3EFB0, ISIN: IL0011948283, 5FC0). oceansix is a technology and manufacturing company on an environmental mission, using plastic waste to create innovative products and build transformative businesses. The company is headquartered in Israel and operates a research and development centre and a production facility in Valencia, Spain.
oceansix Announces the Filing of a Provisional Patent Application for an Innovative Package System
With a continuous commitment to executing its business plan, oceansix marks a significant milestone in its journey towards revolutionising e-commerce packaging. Filed earlier this year, this invention is poised to set new standards in packaging efficiency and reusable systems.
Innovative Design for Sustainable Impact
The package, conceptualised by inventor Gat Ramon, features a unique design that addresses the pressing environmental concerns of traditional single-use packaging. It also solves the critical challenges companies face in ensuring the protection of their items during transit without adding excessive weight or bulk, thereby optimising shipping efficiency.
The packaging is also engineered to adapt to various product sizes, eliminating the need for excess cushioning materials and significantly reducing waste. With its ecological nature, it was designed to be manufactured from recycled materials and to be reused for up to 100 cycles; therefore, it fully aligns with oceansix's mission to foster sustainable practices across industries, particularly businesses where packaging and e-commerce are at their highest peak.
Addressing E-Commerce Challenges
oceansix's package is specifically designed to mitigate the environmental impact of e-commerce, targeting the waste generated by cardboard and plastic materials. The project aims to reduce CO2 emissions and enhance reverse logistics efficiency and cost-effectiveness, offering a scalable and automated-compatible solution that incorporates future features like real-time location tracking and unique identification with smart locking.
oceansix Joins TheCircularLab's goCircular Radar for Circular Economy Excellence
oceansix is honoured to announce its inclusion in the goCircular Radar by TheCircularLab, Europe's pioneering circular economy innovation centre. This distinction places oceansix on the map of leading startups in Europe's circular economy sector, highlighting the reusable packaging project's potential and opening avenues for collaboration.
oceansix Enhances Strategy with Expert Collaboration and New Incentive Options
In addition to our recent announcement about the packaging system, oceansix has granted 300,000 options to a consultant, with a strike price of CAD 0.29, valid for five years. This initiative is a key component of our broader strategy to collaborate with experts whose insights and expertise are vital in propelling our mission forward.
Join oceansix
oceansix invites stakeholders, partners, and the global community to join in its vision of creating impactful and sustainable solutions.
For more information about oceansix and its pioneering projects, please visit oceansix.com and connect with us on LinkedIn.
About oceansix
oceansix Future Paths Ltd. is a leader in developing radical, sustainable solutions and transforming waste into innovative products. Driven by a circular model and a vision to tackle some of Earth's most pressing challenges, oceansix combines advanced technology with sustainable practices to create meaningful solutions and successful global businesses.
Disclaimer
This press release may contain forward-looking statements based on current expectations and assumptions, subject to risks and uncertainties. Actual results may differ materially from those anticipated in these statements. oceansix assumes no obligation to update or revise any forward-looking information.
Approval & Accuracy
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215233336/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom